Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Oct 8, 2026 | News

Calgary, Alberta – October 8, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum...

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Oct 6, 2026 | News

Calgary, Alberta – October 6, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum...

Marvel Biosciences Fait Le Point Sur Un Placement Privé Pouvant Atteindre 3 Millions De Dollars

Sep 17, 2026 | News

Calgary (Alberta), 17 septembre 2026 – Marvel Biosciences Corp. (TSXV : MRVL; OTCQB : MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd’hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser...

Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million

Sep 17, 2026 | News

Calgary, Alberta ‐ September 17, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it intends to...

Marvel Biosciences Annonce la Prolongation de la Date Limite de Clôture du Placement Privé

Sep 9, 2026 | News

Ne pas distribuer aux services de presse américains ni diffuser aux États-Unis Calgary (Alberta), 9 septembre 2026– Marvel Biosciences Corp. (TSXV : MRVL; OTCQB : MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l’approbation de la Bourse de croissance TSX...

Marvel Biosciences Announces Extension to Closing Date of Private Placement

Sep 9, 2026 | News

Calgary, Alberta ‐ September 9, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) announces that it has received approval from the TSX Venture Exchange (“TSXV”) to extend the closing deadline of its...